anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients with cirrhosis who have cognitive complaints are presumed to have hepatic encephalopathy (HE), which leads to unwarranted medications while ignoring the underlying disease process causing these complaints. Since neuropsychological testing, the current gold standard for HE diagnosis, is not readily available, an orderable test is needed. We aimed to develop and validate a rapid gut microbiota test to exclude HE and determine stakeholder input on this approach. Stool was collected from two cohorts: a two-center training cohort (n = 305, on/not on HE-related therapy) and a multicenter validation cohort (n = 30, on HE treatment). Stool microbiota was analyzed rapidly using nanopore analysis. Stakeholder (patients and clinicians) needs assessment was evaluated using semi-quantitative questionnaires. In the training cohort, machine learning using neural network identified a 20-species signature that differentiated HE vs no-HE with 84% specificity compared to the gold standard neuropsychological testing. This high specificity persisted regardless of whether patients were on HE-related therapy or not. In the validation cohort, application of this profile led to reevaluation of the HE diagnosis and treatment in > 40% of the patients. This approach was acceptable to patients (Veterans in the validation cohort) and clinician (n = 40 nationwide) stakeholders. We conclude that a machine learning stool signature based on 20 microbial species developed in a training set and validated in a separate multicenter prospective cohort differentiated those with vs. without HE, identified patients misdiagnosed with HE, and was acceptable to patients and clinician stakeholders.
ABSTRACT OF THE DISCLOSURE This application relates to hair spray compositions having improved holding ability and feel when sprayed onto the hair.  Thus the present specification discloses two different specific resin combinations providing a complete  range of advantageous properties.          These specific resin combinations are based on the discovery that when each of two resins with a good curl-holding ability but each having a feel on the hair, are each combined with a modifying resin to make the feel acceptable, the quality of the curl-holding abilities of the resulting mixture of resins is, surprisingly, essentially equival-ent to the curl-holding ability of the component having a good curl-holding ability in itself.  This is so even if the modifying resin in itself has inferior curl-holding characteristics.  The stiff holding resin is either an octylacrylamidelacrylic acid/ methylmethacrylate copolymer (sold by The National Starch Co. under the trade designation Resin 28-4961, and is referred to hereinafter as "Resin 28-4961") and/ or an octylacrylamide/acrylates/butyaminoethyl methacrylate copolymer wherein the acrylates include to or more monomers consisting of acryl-ic acid, methacrylic acid or any of their simple esters, such as methyl methacrylate and hydroxypropyl methacrylate (sold by The National Starch Co.), having the CTFA name Amphomer in combination with a mod-ifying resin.  The latter is an acrylate/acrylamide copolymer (sold by Ciba-Geigy Corporation under the trade name Ultrahold-8) having the CTFA name Acrylate/acrylalllide copolymer.  A combination of at least one of the aforementioned stiff-holding resins with the Acrylate/ acrylamide copolymer modifying resin is the principal ingredient of the hair spray compositions of the present invention.
This is a FIH, Phase 1/2, open-label, multicenter study to assess safety and determine the maximum tolerated dose (MTD) and/or RP2D of BOXR1030 administration after LD chemotherapy in subjects with GPC3+ advanced solid tumors. After signing informed consent and completing all screening assessments, eligible subjects will be enrolled and undergo leukapheresis to obtain T cells for BOXR1030 manufacturing. Subjects will receive a 3-day LD chemotherapy regimen with fludarabine and cyclophosphamide, administered according to institutional standard practice for these drugs, including inpatient administration as appropriate. Subjects must be hospitalized for BOXR1030 administration and will remain hospitalized for 10 days after the infusion. For 28 days after BOXR1030 administration, all subjects must stay within a distance that requires no more than 2 hours of travel to the study site.

During the Post-treatment Evaluation Period (within 6 months after BOXR1030 administration), study visits will occur daily for the first week, twice in the second week, and then once weekly at Weeks 3, 4, 6, 9, 12, 15, 18, and 24. Safety (targeted physical examination, adverse event \[AE\] assessment, and clinical laboratory tests) will be evaluated and samples will be collected for endpoint analyses. For 28 days after BOXR1030 administration, subjects will be required to monitor their temperature and complete neurological evaluation via the immune effector cell-associated encephalopathy assessment tool every day (to be administered by site staff during clinical visits and by a caregiver at home on non-clinic days). At regular intervals, antitumor activity will be assessed per RECIST 1.1 and iRECIST criteria.

After 6 months of follow-up from BOXR1030 administration, subjects will enter the Long-term Follow-up Period for a total duration of 15 years after BOXR1030 dosing. Study visits are scheduled every 3 months from Month 9 to Month 24, every 6 months thereafter until Year 5, and then annually through Year 15. Long-term follow-up assessments will focus on long-term safety and disease status. Subjects whose disease does not progress before Week 24 will enter the Long-term Follow-up at Month 7. Survival status will be checked at these visits.
Patient receives 120 treatments of Hyperbaric at 1.5 ATA. Non randomized trial. Pt will have cognitive assessments and Spect scans at various treatment points. Oxygen is at 1.5 atmospheric pressure.
Patients receive conjugated estrogens/bazedoxifene orally (PO) once daily (QD) for 28 +/- 7 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
The expected symptoms with overdosage are those of excessive beta-adrenergic receptor stimulation and/or occurrence or exaggeration of any of the symptoms listed under ADVERSE REACTIONS, e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min., arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, and sleeplessness. Hypokalemia also may occur. As with all sympathomimetic medications, cardiac arrest and even death may be associated with the abuse of Xopenex Inhalation Solution. Treatment consists of discontinuation of Xopenex Inhalation Solution together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of Xopenex Inhalation Solution.

The intravenous median lethal dose of levalbuterol HCl in mice is approximately 66 mg/kg (approximately 70 times the maximum recommended daily inhalation dose of levalbuterol HCl for adults and children on a mg/m2 basis). The inhalation median lethal dose has not been determined in animals.
Tuberculosis (TB) is the leading cause of death in people infected with HIV worldwide. South Africa has one of the highest rates of tuberculosis and HIV in sub Saharan Africa and the world. Infection with HIV can result in activation of the latent form of TB to its active form. In places like sub Saharan Africa where the HIV rates are very high TB has spread with incredible vigor. In order to study this phenomenon, we conducted a preliminary project, which demonstrated that there are approximately 250 patients with active TB admitted to one urban South African hospital in one month and that almost half of them are infected with HIV. One quarter of them died while in hospital. They were young people with an average of 32 years. We are interested in undertaking clinical trials that will study novel therapies that can be added to the existing antimicrobial regimens in order to reduce the number of people dying from TB. One of these therapies would be the addition of prednisone, an oral steroid, to the standard TB treatment regimen. Steroids have been shown to be useful in TB meningitis and pericarditis in HIV positive and negative patients. However, steroids have never been tested in a formal manner in HIV patients with pulmonary TB. We have chosen to do our research in South Africa since the numbers of patients needed to design a clinical trial such as the one presented can only be found in such an environment. Prednisone is cheap, easily obtainable and thus a sustainable intervention in developing countries. The impact of the research would affect not only the international community including Canada but would certainly have a lasting sustainable effect on the local community in Pietermaritzburg, South Africa in addition to the rest of the world.
FIELD: medicine, pharmaceutical technology, pharmacy. SUBSTANCE: solid medicinal formula with tranquilizing effect comprises phenazepam as an active component in the following ratio of components, wt.-%: phenazepam, 0.3-1.0; potato starch, 20.0-40.0; gelatin, 0.1-1.0; calcium stearate and/or stearic acid, 0.3-1.0; lactose, the balance. Method for preparing solid medicinal formula involves preliminary preparing phenazepam trituration by mixing phenazepam with part of total lactose amount, preparing granulate from prepared phenazepam trituration, potato starch and remained amount of lactose with gelatin an aqueous solution as granulating liquid, powdering granulate with calcium stearate and/or stearic acid and tableting. Phenazepam tablets exhibit satisfactory capacity for decomposition being without irritant effect of digestive tract and providing high tranquilizing activity simultaneously. EFFECT: improved preparing method, valuable pharmaceutical properties of drug. 5 cl, 1 tbl, 1 ex
This MISC version (MISC-SA) aims to transfer the MISC original training to wider communities by diminishing the cost of the teaching and learning. By implementing the MISC lessons in an online platform, thus allowing self-learning, the new Self- Administered version of MISC allows to obtain MISC training in 30 weekly sessions distributed across 12 months, in 2 blocks: 18 sessions from February to June, and 12 additional sessions from October to December. In contrast to the original version of MISC, this version allows the simultaneous self-training of a high number of participants with very low intervention of a supervisor, which diminishes the cost. MISC-SA keeps the core component of MISC training (video-feedback) by fostering participants to record interactions and then visualize them using guided reﬂection.
Carcinogenesis: Long-term studies in animals to evaluate carcinogenic potential have not been conducted with sulfamethoxazole and trimethoprim.

Mutagenesis: Bacterial mutagenic studies have not been performed with sulfamethoxazole and trimethoprim in combination. Trimethoprim was demonstrated to be nonmutagenic in the Ames assay. No chromosomal damage was observed in human leukocytes In vitro with sulfamethoxazole and trimethoprim alone or in combination; the concentrations used exceeded blood levels of these compounds following therapy with sulfamethoxazole and trimethoprim. Observations of leukocytes obtained from patients treated with sulfamethoxazole and trimethoprim revealed no chromosomal abnormalities.

Impairment of Fertility: No adverse effects on fertility or general reproductive performance were observed in rats given oral dosages as high as 350 mg/kg/day sulfamethoxazole plus 70 mg/kg/day trimethoprim.
The present invention provides three-dimensional hydrogel structures patterned by a treated micropattern mold. The treated mold is capable of transferring the inverse of its micropattern to a hydrogel by contact during formation or polymerization of the structure from a precursor. The treated micropattern mold surface allows the mold to be separated from the hydrogel without collapsing the structure or irreparably damaging its micropattern. The transferred micropattern may yield individual features and/or interconnected channels in the hydrogel. The invention also provides a hydrogel network fabricated by interfacing at least two hydrogels in which one or more of the hydrogels may be a micropatterned structure. Micropatterned hydrogel structures can also be specifically aligned to interconnect their patterns. Structures or networks of the invention comprise hydrogels that can adhere together by chemically bonding and/or mechanically entangling.
The investigators will perform a feasibility and pilot study evaluating relaxation response (narration leading through deep-breathing, mindfulness, and other relaxation techniques) followed by VR in patients with sickle cell disease (SCD) and caner. The VR headset (NeuTab VR Virtual Reality Headset, Dynamic Virtual Viewer, or similar device) used will be compatible with an iPhone purchased by the PI. The VR session will be narrated by Jon Seskevich, RN. Patients will be provided with a second iPhone to play the recording while the other iPhone is used to display the VR session.

The patients will first be provided a consent form and consented. They will have the opportunity to ask questions prior to and following consent. They will subsequently give a pain score and fill out a GAD-7 (Generalized Anxiety Disorder) and PHQ-9 (Patient Health Questionnaire) form. They will be taught how to use the VR headset. Patients will listen to a recording by Jon Seskevich, RN of a ten-minute relaxation response. An iPhone will then be placed in the VR headset, the recording started, and the headset placed on the patient. The VR scene is available through Provata VR app and has been previously chosen prior to the start of the study. Following this, patients will again give a pain score as well as complete another GAD-7, PHQ-9, Presence Questionnaire, and Patient's Global Impression of Change (PGIC) form. Patients will be asked to fill out pain score and general health questions via the TRU-Pain app. Patients will then be able to ask questions/provide further feedback.
A total of 120 participants with fibromyalgia will be randomly assigned to one of four intervention groups (Operant Learning (OL), Energy Conservation (EC), delayed-OL and delayed-EC). The delayed groups will receive the AP intervention 3 months later and will serve as a Usual Care control group. All groups will continue to receive any concomitant interventions that they are receiving (pharmacological and non-pharmacological) at the time of enrollment.
PURPOSE:To obtain an ultraviolet absorber and a skin preparation for external use excellent in ultraviolet absorbing actions and further stability, safety and protecting actions on the skin. CONSTITUTION:This ultraviolet absorber comprises a pyrroloquinoline qinone ester of formula I (R1 and R2 are independently each alkyl, alkenyl, aralkyl, alaryl or phenyl having a short chain length or H; at least one of R1, R2 and R3 is not H) and/or its salt, e.g. pyrroloquinoline monoallyl ester of formula II. The compound of formula I is obtained by reacting, e.g. pyrroloquinoline quinone or its salt compound with alcohols under acidic conditions. This skin preparation for external use is prepared by blending one or more of the ultraviolet light absorbers in an amount of preferably 0.01-10wt.%, more preferably 0.1-1wt.% based on the total amount of the preparation for external use.
Cataract surgery is the most common surgical operation in the developed world, for treating cataracts, currently the leading cause of blindness worldwide. Retinal detachment (RD) is a potentially sight-threatening adverse effect of cataract surgery. The overall RD case numbers are high due to the common practice of cataract surgery. The Medline, Scopus, and Directory of Open Access Journals databases were searched for relevant articles using the keywords (phacoemulsification OR cataract surgery) AND (retinal detachment, detached retina). The included studies involved 5,480,448 patients, where 36,886 had RD (pooled incidence: 0.66 events per 100 patients, 95% CI 0.43 to 1.00). Male patients had significantly higher odds of developing RD than female patients (odds ratio = 1.73, 95% CI 1.68 to 1.78, P < 0.001). The RD incidence rate across locations was not significantly different. RD is one of the most significant complications following cataract surgery. [Ophthalmic Surg Lasers Imaging Retina 2024;55:668-674.].
Active Cycle of Breathing Technique ACBT is a method of breathing performed in a cycle, used to help loosen and clear secretions from within the lungs (Panaligan et al., 2012). It consists of three different phases.
The conventional management of patients with mild cognitive impairment focuses on therapies such as cognitive rehabilitation, occupational therapy, and physical exercise, with medical monitoring as needed according to the patient's needs. Additionally, they will receive information about infectious diseases such as dengue, pneumonia, tuberculosis, Chagas disease, leishmaniasis, COVID-19, leprosy, urinary tract infection, rabies, superficial and cutaneous mycoses, and hepatitis one topic per week through an infographic and video sent to the cell phone.
The dermatoscopic characteristics of shiny white structures (SWS) in malignant skin tumours are well described, but data on benign skin neoplasms are scarce. To evaluate the dermatoscopic features of SWS in common benign tumours, we reviewed our database for histopathologically confirmed cases. Dermatoscopic images were evaluated for the presence of any type of SWS. Images with SWS were further analysed for their quantity, distribution and shape. Of 2420 evaluated benign tumours, 357 (14.8%) displayed SWS. The highest frequencies were observed in pyogenic granuloma (n = 62/100; 62%), angioma (n = 63/113; 55.8%) and adnexal tumours (n = 42/84; 50%). The lowest frequency was found in common naevi (n = 16/1032; 1.6%) and solar lentigo (n = 0). The presence of SWS was not associated with sex or anatomical location. SWS were usually diffuse and multiple. SWS may be present in a broad spectrum of benign tumours and therefore they should not be considered as de facto indicators of malignancy.
Embodiments of the present disclosure relate to methods, apparatuses, and media for data processing. According to various embodiments, textual information for report presentation and coordinate location information associated with the textual information are determined. A first set of text elements corresponding to the at least one inspection item is determined based on the coordinate location information and the text information. And determining the entity category to which the text element in the first text element set belongs by using the entity recognition model. Entity recognition models have been trained based on multiple types of reports. A structured data representation for the report is generated based on the first set of text elements and the determined entity category. The structured data representation comprises at least one data record corresponding to at least one inspection item. Each data record includes an identifier corresponding to a text element of the inspection item and to the entity class to which the text element belongs. The generated structured data representation can facilitate retrieval of patient information, subsequent diagnosis, and other operations.
The invention provides a natural vegetal and mineral composite anti-cancer pharmaceutical composition, a preparation and a preparation method of the preparation. The anti-cancer pharmaceutical composition is prepared from rhinoceros horn, oldenlandia diffusa, dried radix rehmanniae, aloe, tortoise plastron, turtle shells, cortex lycii radicis, radix angelica sinensis, American ginseng, Mesona chinensis Benth., radix scutellariae powder, resina draconis, scutellariae barbatae, achyranthes bidentata, costusroot, musk and gypsum. The preparation is prepared with the anti-cancer pharmaceutical composition as the active raw material. The raw material powder is embedded by organic grease, is detoxified at high temperature, cooled at low temperature, and then polymerized and smashed to obtain solid preparation. The solid preparation and myoglobin are steamed with water without making contact with water, and a liquid preparation of a decoction is obtained after filtering. The raw material medicines are used together to achieve the functions of strengthening the body resistance to eliminate pathogenic factors, enhancing immunity and regulating and improving microcirculation. Meanwhile, by means of breast protection for immunity improvement, immune surveillance is improved, cancer cell reversion or apoptosis is induced, stasis elimination and pain relieving are achieved and cell aggregation is dispersed, so that cancer cells cannot survive or necessary internal or external conditions for growth of cancer cells are eliminated. The whole treatment process is free of toxic and side effects.
The assessment of severity of TBI patients is based on the Glasgow Coma Scale (GCS) and the initial management in the ED includes performing a non-contrast brain Computed Tomography (CT) scan if the patient meets specific conditions. To date, real world data show that EDs would actually not follow guideline recommendations and a substantial CT overuse is observed. Management strategies are becoming more and more focused on selective CT use to effectively manage health care resources. Efforts have been made to optimize the indications for brain CT scan after mTBI. Although brain CT scan plays a central role after mTBI, there is an unmet clinical need for an objective tool to optimize indications for CT scan, reduce patient radiation exposure, and possibly predict patient outcome. Clinical Decision Rules for an initial CT-scan could be optimized by the use of an objective parameter easily and rapidly measured. This may be the place for serum biomarkers providing a quick and accurate assessment. BioMérieux has now developed an automated assay for the measurement of serum Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase (UCH-L1), the VIDAS® TBI assay to fill out this unmet needs. The goal of the herein study is to generate real-world data and evidences to support the VIDAS® TBI performances.
<P>PROBLEM TO BE SOLVED: To provide a means useful for the diagnosis/prevention/treatment of angiitis, and to provide a means for improving the accuracy of the diagnosis/treatment or the like of angiitis.  <P>SOLUTION: A group of nucleic acid molecules is provided, wherein each of the molecules comprises the respective nucleotide sequences or partial sequences thereof or complementary sequences thereof of multiple genes selected from a gene group being in specific expression in cells existing in target peripheral blood suffered from angiitis. A group of antibodies is also provided, wherein each of the antibodies is specifically bound to the respective translation products of multiple genes selected from a gene group being in specific expression in cells existing in target peripheral blood suffered from angiitis. Besides, a method for diagnosing angiitis is also provided, comprising analyzing a gene group being in specific expression in cells existing in target peripheral blood suffered from angiitis. Furthermore, a method for identifying a curative for angiitis and a method of preparing data for the inspection criteria for angiitis are also provided, respectively.  <P>COPYRIGHT: (C)2007,JPO&INPIT